Endo Wins Dismissal Of FTC's Suit Over Impax Opioid Deal
Endo Pharmaceuticals on Thursday secured a D.C. federal court's dismissal of the Federal Trade Commission's antitrust suit accusing it of entering a second "pay-for-delay" agreement with Impax Laboratories to stave off...To view the full article, register now.
Already a subscriber? Click here to view full article